Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Primary Care Dementia Data

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

Lilly launches global Alzheimer’s campaign with Julianne Moore

The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

- PMLiVE

TRIMTECH Therapeutics establishes Scientific Advisory Board

Alessio Ciulli has been appointed as Chair of the board

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

Navigating NHS Market Access: Policy Change and Opportunity in England With Sarah Everest Ford

Navigating NHS Market Access: Policy Change and Opportunity in England

With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...

Petauri Evidence

- PMLiVE

Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency

Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...

Petauri Evidence

- PMLiVE

Roche shares promising data from Alzheimer’s disease development portfolio

The company is planning to initiate phase 3 studies of trontinemab in early AD this year

- PMLiVE

UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

It is hoped that the test could be available for widespread UK use in the coming years

- PMLiVE

Live Q&A: Beyond NHS England – Navigating changes at NHSE and DHSC

What impact can we expect from the abolition of NHS England (NHSE) and changes at the Department of Health and Social Care (DHSC)? What do these changes mean for your...

Petauri Evidence

- PMLiVE

GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn

The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform

- PMLiVE

Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

GSK to explore link between Shingrix and dementia risk in new UK research collaboration

More than 55 million people worldwide are currently living with the neurodegenerative disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links